Peptides and peptide conjugates: therapeutics on the upward path

Author:

Ahrens Verena M1,Bellmann-Sickert Kathrin1,Beck-Sickinger Annette G2

Affiliation:

1. Institute of Biochemistry, Faculty of Biosciences, Pharmacy & Psychology, Universität Leipzig, Brüderstraße 34, 04103 Leipzig, Germany

2. Institute of Biochemistry, Faculty of Biosciences, Pharmacy & Psychology, Universität Leipzig, Brüderstraße 34, 04103 Leipzig, Germany.

Abstract

The main benefit of natural peptides, peptide analogs and newly designed peptides as therapeutics, lies in their high selectivity and affinity, which are frequently in the nanomolar range. New drugs targeting protein–protein interactions often require larger interaction sites than small molecules can offer. Thus, many peptidic drugs are already applied in therapy at the current state. The next generation of peptide-based therapeutic agents is currently on its way from basic research to clinical studies and eventually to the pharmaceutical market. Development of more robust and long-lasting drugs owing to well-known and new stabilization strategies is yielding novel and continuously improving peptide drugs. The introduction of smart linkers that exhibit stability towards blood plasma but intracellular lability will lead to target-oriented activity, which might successfully decrease side effects. In this review, peptidic therapeutics on the market, in clinical studies and some of those in basic research are characterized. Stabilization strategies and intelligent linkers are discussed with respect to their use in peptide drug therapy.

Publisher

Future Science Ltd

Subject

Drug Discovery,Pharmacology,Molecular Medicine

Reference105 articles.

1. US FDA.Approved Drug Products with Therapeutic Equivalence Evaluation. Division of Drug Information, Silver Spring, MD, USA,31(2011).

2. Part I: Milestones in personalised medicine—imatinib

3. WATCHING PEPTIDE DRUGS GROW UP

4. Expression in Escherichia coli of a Chemically Synthesized Gene for the Hormone Somatostatin

5. Chemical synthesis of genes for human insulin.

Cited by 129 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3